stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Free cash flow
Genmab A/S Sponsored ADR's free cash flow for fiscal 2025 was −$6.1B, compared with $1.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was −$6.3B. Over the past ten years it has ranged from −$6.1B (fiscal 2025) to $1.1B (fiscal 2024) — the current reading is the lowest in ten years. Genmab A/S Sponsored ADR ranks 603rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$6.1B | — |
| FY2024 | $1.1B | 3.73% |
| FY2023 | $1.0B | 99.78% |
| FY2022 | $509.1M | 61.92% |
| FY2021 | $314.4M | (66.50%) |
| FY2020 | $938.5M | 415.30% |
| FY2019 | $182.1M | 113.95% |
| FY2018 | $85.1M | (66.73%) |
| FY2017 | $255.9M | 449.98% |
| FY2016 | $46.5M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $48.0M | — |
| Mar 2026 | −$2.0M | — |
| Dec 2025 | −$6.9B | — |
| Sep 2025 | $534.0M | 926.92% |
| 26 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| RPRX Royalty Pharma PLC compare | $3.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $806.3M |
| INCY Incyte Corporation compare | $679.9M |
| BNTX BioNTech SE Sponsored ADR compare | −$524.1M |
| INSM Insmed, Inc. compare | −$627.6M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
| GMAB Genmab A/S Sponsored ADR | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement